Last reviewed · How we verify
NCT04780789
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
trial testing Transarterial Chemoembolization in Hepatocellular Carcinoma in 61 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | Brno University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 61 |
| Start date | 1 February 2015 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
Drugs / interventions tested
- Transarterial Chemoembolization — full drug profile →
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
- Hepatocellular Carcinoma by BCLC Stage — all drugs for Hepatocellular Carcinoma by BCLC Stage →
Sponsor
Brno University Hospital
Who can join
18 and older, any sex, with Hepatocellular Carcinoma or Hepatocellular Carcinoma by BCLC Stage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The application of transarterial chemoembolisation (TACE) with drug-eluting beads in patients with hepatocellular carcinoma and its response to the treatment will be observed. The registry has the following objectives: To assess the response to the treatment by standard methods and volumetric analysis as well as trying to determine any predictive response factors To determinate interobserver variability of the methods.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival.
Hajkova M, Andrasina T, Ovesna P, Rohan T, et al · · 2022 · cited 4× · PMID 36099102 · DOI 10.21873/invivo.12964
Verify or expand the search:
- PubMed search for NCT04780789
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transarterial Chemoembolization
Trials testing the same drug.
- NCT06261814 — Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors · Phase 2 · recruiting
- NCT06503250 — A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevac · completed
- NCT05672108 — Phase II Trial of Lung Chemoemobolization · Phase 2 · recruiting
- NCT05361161 — Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC) · Phase 2 · unknown
- NCT05233358 — HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure · NA · unknown
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Brno University Hospital trials
Trials by the same sponsor.
- NCT07468006 — Comparison of Transcutaneous and Blood CO₂ Measurement in Critically Ill Children · recruiting
- NCT07280039 — Mortality and Muscle Mass Loss in Critically Ill Patients. · not yet recruiting
- NCT07279701 — The Effect of Near-infrared Spectroscopy on the Success of Peripheral Venous Access · NA · recruiting
- NCT07245654 — Monitoring the Depth of Anesthesia and Nociception During the Induction of General Anesthesia in Pediatric Patients · recruiting
- NCT07110012 — The Role of Simulation-based Training in Resident Curriculum in Anaesthesia and Intensive Care · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04780789 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brno University Hospital
- Last refreshed: 4 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04780789.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing